Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H5N1 avian influenza VLP vaccine
- Development stage
- Unknown
- Lead developer
- Medicago
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
The H5N1 avian influenza VLP vaccine is a vaccine candidate developed by Medicago Inc. and the Infectious Disease Research Institute (IDRI) for pandemic preparedness against H5N1 avian influenza. It utilizes Medicago's proprietary plant-based virus-like particle (VLP) technology, produced in Nicotiana benthamiana, combined with IDRI's Glucopyranosyl Lipid A (GLA) adjuvant to enhance immune responses. The vaccine aims to provide improved speed of production, immune breadth, and dose efficiency. It has undergone a Phase I clinical trial to assess its safety and immunogenicity in healthy adults.
- Other names
- H5N1 Virus-Like Particle (VLP) Influenza Vaccine (Recombinant)
Beyond the preview
Go deeper on H5N1 avian influenza VLP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H5N1 avian influenza VLP vaccine.